GW&K Investment Management LLC Sells 61,418 Shares of AtriCure, Inc. (NASDAQ:ATRC)

GW&K Investment Management LLC trimmed its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 805,109 shares of the medical device company’s stock after selling 61,418 shares during the quarter. GW&K Investment Management LLC owned approximately 1.70% of AtriCure worth $28,734,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ATRC. RiverPark Advisors LLC acquired a new position in AtriCure in the 3rd quarter worth about $27,000. Allspring Global Investments Holdings LLC increased its stake in AtriCure by 31.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,074 shares of the medical device company’s stock valued at $91,000 after purchasing an additional 497 shares during the last quarter. Quest Partners LLC purchased a new position in shares of AtriCure during the fourth quarter worth about $103,000. Victory Capital Management Inc. grew its stake in AtriCure by 22.9% during the 4th quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock worth $221,000 after buying an additional 1,155 shares during the last quarter. Finally, HighMark Wealth Management LLC boosted its stake in AtriCure by 223.0% during the 4th quarter. HighMark Wealth Management LLC now owns 9,125 shares of the medical device company’s stock worth $326,000 after purchasing an additional 6,300 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AtriCure

In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $24.09, for a total transaction of $36,135.00. Following the sale, the insider now directly owns 71,284 shares in the company, valued at $1,717,231.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Justin J. Noznesky sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $24.09, for a total transaction of $36,135.00. Following the completion of the transaction, the insider now directly owns 71,284 shares in the company, valued at $1,717,231.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Karl S. Dahlquist sold 8,231 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total value of $307,510.16. Following the sale, the insider now owns 52,839 shares in the company, valued at approximately $1,974,065.04. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,616 shares of company stock valued at $504,932. 3.20% of the stock is currently owned by corporate insiders.

AtriCure Stock Performance

Shares of NASDAQ ATRC traded up $0.09 during midday trading on Wednesday, reaching $22.54. 43,319 shares of the stock were exchanged, compared to its average volume of 698,719. AtriCure, Inc. has a 12 month low of $20.19 and a 12 month high of $59.61. The business has a 50-day simple moving average of $25.77 and a two-hundred day simple moving average of $32.11. The company has a current ratio of 4.00, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $108.90 million for the quarter, compared to the consensus estimate of $106.86 million. AtriCure had a negative return on equity of 7.85% and a negative net margin of 8.98%. The company’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.23) earnings per share. On average, analysts anticipate that AtriCure, Inc. will post -0.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ATRC shares. Needham & Company LLC cut their price target on shares of AtriCure from $46.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Stifel Nicolaus lowered their target price on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a report on Friday, February 16th. UBS Group boosted their price objective on shares of AtriCure from $57.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Oppenheimer raised shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a research report on Tuesday, April 23rd. Finally, StockNews.com lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.78.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.